Status of trail | Condition | Interventions of clinical trial | Phase | Completion time |
---|---|---|---|---|
Completed | • BC • Advanced solid tumors | • Drug: Neratinib and vinorelbine | Phases 1 and 2 | 2018 |
Completed | • Breast neoplasms | • Drug: Neratinib | Phase 2 | 2018 |
Completed | • Advanced BC | • Drug: HKI-272 and trastuzumab | Phases 1 and 2 | 2018 |
Completed | • Advanced BC • Advanced solid tumors, breast neoplasms | • Drug: HKI-272 and paclitaxel | Phases 1 and 2 | 2018 |
Active, not recruiting | • BC | • Drug: Neratinib and placebo | Phase 3 | 2020 |
Completed | • BC | • Drug: Neratinib and capecitabine | Phases 1 and 2 | – |
Recruiting | • BC | • Drug: HKI-272, Capecitabine, Ado Trastuzumab Emtansine | Phase 2 | 2023 |
Completed | • Breast neoplasms | • Drug: Neratinib | Phase 1 | 2007 |
Completed | • BC | • Drug: Neratinib, trastuzumab and paclitaxel | Phase 2 | 2018 |
Completed | • Advanced BC • BC | • Drug: Neratinib, lapatinib and capecitabine | Phase 2 | 2018 |
Completed | • BC | • Drug: Temsirolimus and neratinib | Phases 1 and 2 | 2016 |